Melanoma in Dogs: Skin vs Oral, Diagnosis, and Treatment

By Emiel Maddens  ·  Reviewed in consultation with licensed veterinary professionals  ·  Updated June 2026  ·  10 min read

Photo by Anya Prygunova on Unsplash

The word melanoma understandably triggers fear in both human and veterinary medicine. In dogs, however, melanoma behavior is far more nuanced than many owners realize, and the location of the tumor is the single most important factor in determining whether it is benign or malignant. Understanding the critical differences between cutaneous (skin) melanomas and oral or mucocutaneous melanomas can help you respond appropriately if your dog is diagnosed with one of these tumors.

Cutaneous melanomas in dogs are, for the most part, benign tumors that behave as well-circumscribed, slow-growing skin masses with minimal metastatic potential. Complete surgical excision is usually curative. In stark contrast, oral melanomas are the most common malignant tumor of the oral cavity in dogs and carry a significantly more guarded prognosis, with high rates of local tissue invasion and spread to regional lymph nodes and lungs. Melanomas arising on digits, at mucocutaneous junctions (the lip margins, eyelids, and nasal planum), and in the nail bed also tend toward malignant behavior.

This article provides a thorough overview of melanoma in dogs, covering cutaneous and oral forms, diagnostic approaches, staging, treatment options including the melanoma vaccine, and what to expect after diagnosis.

Cutaneous Melanoma: Usually Benign in Dogs

Clinical Presentation

Cutaneous melanomas in dogs present as solitary, well-circumscribed, dome-shaped nodules on haired skin. They range in size from a few millimeters to several centimeters and may be darkly pigmented (black or dark brown), lightly pigmented, or completely amelanotic (lacking visible pigment). Most cutaneous melanomas are firm, freely movable over underlying tissues, and covered by intact or slightly thinned skin. Common locations include the head, trunk, and proximal limbs. Growth is typically slow and steady rather than rapidly progressive. Dogs of all breeds can develop cutaneous melanomas, though darkly pigmented breeds such as Scottish Terriers, Miniature and Standard Schnauzers, Doberman Pinschers, and Golden Retrievers are predisposed.

Benign vs Malignant Behavior

Approximately 80 to 85 percent of cutaneous melanomas in dogs on haired skin are benign melanocytomas. These tumors grow by expansion rather than invasion, do not metastasize, and are cured by complete surgical excision. The remaining 15 to 20 percent are malignant melanomas that can behave more aggressively, with potential for local invasion and distant metastasis. Histopathological features that predict malignant behavior include high mitotic index (more than three mitotic figures per ten high-power fields), nuclear atypia, ulceration, and deep tissue invasion. The Ki-67 proliferation index provides additional prognostic information, with higher values indicating greater malignant potential. Importantly, the degree of pigmentation does not reliably predict behavior, as both benign and malignant cutaneous melanomas can be heavily pigmented or amelanotic.

Treatment of Cutaneous Melanoma

Complete surgical excision with clean margins is the treatment of choice for cutaneous melanomas and is curative for the vast majority of benign melanocytomas. Margins of one to two centimeters laterally and one fascial plane deep are generally recommended, though the exact margins may be adjusted based on tumor size, location, and pre-surgical biopsy results. The excised tissue should always be submitted for histopathology to confirm the diagnosis, assess margins, and determine the mitotic index and other prognostic indicators. For the uncommon malignant cutaneous melanoma, staging (lymph node aspiration and thoracic radiographs or CT) and potentially adjuvant therapy may be recommended. Dogs with completely excised benign melanocytomas have an excellent prognosis, with recurrence rates below 5 percent.

Oral Melanoma: Aggressive and Dangerous

Why Oral Melanoma Is Different

Oral melanomas arise from melanocytes in the mucous membranes of the oral cavity, including the gums, palate, tongue, and buccal mucosa. Unlike their cutaneous counterparts, oral melanomas are almost universally malignant and aggressive. The reasons for this location-dependent behavior are not fully understood but likely relate to differences in the microenvironment, growth factor signaling, and immune surveillance between haired skin and mucosal tissue. Oral melanomas have a high rate of local tissue invasion, frequently involving the underlying bone, and metastasize to regional lymph nodes and lungs in 70 to 80 percent of cases. Oral melanoma is the most common malignant oral tumor in dogs, accounting for approximately 30 to 40 percent of all oral malignancies, and it carries a significantly more guarded prognosis than cutaneous melanoma.

Clinical Signs and Detection

Oral melanomas are often discovered incidentally during dental examinations, routine veterinary visits, or by owners who notice a mass while feeding or playing with their dog. Signs that may alert owners include bad breath (halitosis), bloody saliva, difficulty eating, drooling, facial swelling, loose teeth, or reluctance to chew toys. The tumors may appear as raised, pigmented masses on the gums or palate, but a significant percentage (up to one-third) are amelanotic, presenting as pink or red masses that lack the dark pigmentation typically associated with melanoma. This lack of pigmentation can lead to misidentification and delayed diagnosis. Any oral mass in a dog should be taken seriously, regardless of its color, and should be evaluated with biopsy or fine needle aspiration.

Staging Oral Melanoma

Staging is critical for oral melanoma because it determines prognosis and guides treatment decisions. The WHO staging system for oral melanoma is based primarily on tumor size: Stage I tumors are less than 2 centimeters, Stage II tumors are 2 to 4 centimeters, and Stage III tumors are greater than 4 centimeters or have lymph node metastasis. Stage IV indicates distant metastasis. Staging workup includes thorough oral examination under anesthesia, aspiration of the regional (mandibular and retropharyngeal) lymph nodes, three-view thoracic radiographs or thoracic CT to screen for lung metastases, and advanced imaging (CT or MRI) of the oral cavity to assess the extent of bone involvement. Abdominal imaging may be included to evaluate for distant metastatic disease. Staging provides essential information for treatment planning and allows for more accurate prognostic discussions with the owner.

Prognosis for Oral Melanoma

The prognosis for oral melanoma depends heavily on stage at diagnosis. Median survival times without treatment are approximately two to three months. With surgery alone, median survival varies by stage: approximately 17 to 18 months for Stage I, 5 to 6 months for Stage II, and 3 months for Stage III. The high metastatic rate means that even when local control is achieved through surgery, many dogs eventually succumb to metastatic disease. However, multimodal treatment combining surgery, radiation, and immunotherapy has improved outcomes for some patients. The melanoma vaccine (discussed below) has shown promise in extending survival times, particularly for dogs with local disease control after surgery or radiation.

Regular oral and skin examinations help detect melanomas and other tumors at earlier, more treatable stages.

Photo by Karsten Winegeart on Unsplash

Other High-Risk Melanoma Locations

Digital (Toe) Melanoma

Melanomas arising on the digits or in the nail bed are another location-specific form that tends toward malignant behavior. Digital melanoma is one of the most common malignant tumors of the canine digit and frequently involves the underlying bone, causing lytic (bone-destroying) changes visible on radiographs. Common presenting signs include swelling of a toe, lameness, bleeding from the nail bed, and loss of the toenail. Darkly pigmented breeds, particularly Schnauzers and Scottish Terriers, are overrepresented. Diagnosis requires biopsy, and staging should include digital radiographs, regional lymph node aspiration, and thoracic imaging. Amputation of the affected digit is the standard surgical treatment and provides excellent local control. Prognosis depends on the presence or absence of metastasis at diagnosis, with median survival times of approximately one year for dogs without metastatic disease at presentation.

Mucocutaneous Junction Melanoma

Melanomas arising at mucocutaneous junctions, the transitional zones where skin meets mucous membrane (such as the lip margins, eyelids, prepuce, vulva, and perianal area), tend to behave more aggressively than melanomas on haired skin. These tumors share some biological characteristics with oral melanomas and have a higher metastatic rate than typical cutaneous melanocytomas. The lip margin is a particularly important site, as tumors here may be classified as either cutaneous or oral depending on their exact location, with significant prognostic implications. Any melanocytic tumor at a mucocutaneous junction should be treated with wider margins and staged for metastatic disease, similar to the approach for oral melanoma.

Melanoma of the Eye

Melanocytic tumors can arise within the eye, specifically from the uveal tract (iris, ciliary body, or choroid). Uveal melanomas in dogs are typically benign and may be monitored for years without treatment if they are not causing clinical problems. However, some uveal melanomas can cause secondary glaucoma by obstructing aqueous humor outflow, which is painful and vision-threatening. When uveal melanoma causes glaucoma or significant intraocular disease, enucleation (eye removal) is typically recommended. The prognosis after enucleation for uveal melanoma in dogs is generally good, with metastatic rates much lower than those seen with oral or digital melanomas. Regular ophthalmic examinations are important for dogs with known uveal melanocytic lesions to monitor for growth and secondary complications.

Treatment Approaches for Malignant Melanoma

Surgery

Surgical excision remains the primary treatment for melanoma at any location. For cutaneous melanocytomas, conservative excision is sufficient. For malignant oral melanomas, aggressive surgery with wide margins is needed, which may involve partial mandibulectomy (removal of a portion of the lower jaw) or maxillectomy (removal of a portion of the upper jaw). While these procedures sound daunting, dogs typically recover well and adapt remarkably to the altered anatomy, maintaining good quality of life, normal eating, and a cosmetically acceptable appearance. The goal of surgery is to achieve complete local control, as incomplete excision of malignant melanoma has high local recurrence rates. When complete surgical excision is not feasible due to tumor size or location, debulking surgery followed by radiation therapy may be recommended.

Radiation Therapy

Melanoma was traditionally considered a radiation-resistant tumor, but modern hypofractionated (large dose per fraction) radiation protocols have demonstrated meaningful response rates for canine oral melanoma. Protocols typically deliver four to six treatments of 8 to 10 Gray each, given once weekly. Overall response rates of 70 to 80 percent have been reported, with many tumors showing complete clinical regression. Radiation is particularly useful for tumors that are too large for surgical excision or in cases where surgery would result in unacceptable functional or cosmetic outcomes. Radiation alone does not prevent metastatic disease, so it is often combined with systemic therapy for the best overall outcomes. Side effects are generally limited to the irradiated area and may include mucositis (oral inflammation), skin reactions, and temporary eye irritation if the orbit is within the treatment field.

The Canine Melanoma Vaccine (ONCEPT)

ONCEPT is a USDA-licensed therapeutic DNA vaccine designed to stimulate an immune response against canine melanoma. The vaccine contains a gene encoding human tyrosinase, a key enzyme in melanin production. When injected intramuscularly using a transdermal delivery device, the vaccine prompts the dog's immune system to produce antibodies and T-cells against tyrosinase. Because canine and human tyrosinase proteins are similar but not identical, the human version is sufficiently foreign to trigger a robust immune response that cross-reacts with the canine tyrosinase expressed by melanoma cells. The vaccine is administered in an initial series of four doses given two weeks apart, followed by booster doses every six months. ONCEPT is approved as an adjunctive treatment for dogs with locally controlled (surgically excised or irradiated) oral melanoma at Stage II or III, and clinical experience suggests it may improve survival times when combined with effective local therapy.

Chemotherapy and Newer Therapies

Traditional chemotherapy has limited efficacy against canine melanoma, with most conventional chemotherapy agents producing response rates below 30 percent. Carboplatin, the most commonly used single agent, has shown modest activity. However, the landscape of melanoma treatment is evolving with immunotherapy approaches beyond the melanoma vaccine. Checkpoint inhibitor therapy, which has transformed human melanoma treatment, is an active area of research in veterinary oncology. Several clinical trials are investigating canine-specific checkpoint inhibitors targeting the PD-1/PD-L1 pathway. Metronomic (low-dose, continuous) chemotherapy protocols using drugs like cyclophosphamide and non-steroidal anti-inflammatory drugs are also being explored for their anti-angiogenic and immunomodulatory effects. The combination of local control through surgery or radiation with systemic immunotherapy represents the current best practice for maximizing survival in dogs with malignant melanoma.

Living with a Melanoma Diagnosis

Follow-Up and Monitoring

After melanoma treatment, regular follow-up is essential to monitor for local recurrence and metastatic disease. A typical monitoring schedule includes re-examination every two to three months for the first year, then every three to four months thereafter. Each visit should include a thorough oral (or site-specific) examination, palpation of regional lymph nodes, and thoracic radiographs or CT to screen for pulmonary metastases. For dogs receiving the melanoma vaccine, monitoring serum anti-tyrosinase antibody levels may provide information about the immune response to the vaccine, though this is not universally available. Prompt attention to any new masses, changes in appetite, breathing difficulties, or general health decline allows for early detection and management of recurrent or metastatic disease.

Quality of Life Considerations

Maintaining quality of life is the paramount goal in managing dogs with melanoma, particularly when the prognosis is guarded. Dogs that have undergone mandibulectomy or maxillectomy for oral melanoma typically adapt quickly to their altered anatomy and return to normal eating, drinking, and play within weeks. Pain management using multimodal analgesic protocols ensures comfort during recovery and ongoing care. Nutritional support may be needed during treatment, particularly if radiation-induced mucositis temporarily reduces appetite. The decision to pursue aggressive treatment should always be weighed against the expected quality of life benefits, and honest discussions with your veterinary oncologist about realistic expectations are an important part of the decision-making process.

Preventive Screening for High-Risk Breeds

While melanoma cannot be prevented, early detection significantly improves outcomes. Owners of breeds predisposed to melanoma, including Schnauzers, Scottish Terriers, Cocker Spaniels, Gordon Setters, Chow Chows, and Golden Retrievers, should perform regular oral and skin examinations. Lift your dog's lips to inspect the gums, palate, and inner cheek surfaces monthly, looking for any masses, color changes, or areas of bleeding. Check the digits and nail beds for swelling, discharge, or nail loss. Examine the skin during regular grooming, noting any new pigmented or non-pigmented growths. Report any findings to your veterinarian promptly, as early-stage melanomas have significantly better treatment outcomes than advanced-stage disease.

Melanoma in Dogs FAQ

Q: Are all melanomas in dogs cancerous?

No. In dogs, the behavior of melanoma depends heavily on location. Approximately 80 to 85 percent of melanomas on haired skin are benign melanocytomas that are cured by simple surgical removal. In contrast, melanomas in the oral cavity, on digits, and at mucocutaneous junctions are almost always malignant. This location-dependent behavior is one of the most important distinctions in veterinary oncology and determines the approach to treatment and follow-up.

Q: What are the signs of oral melanoma in dogs?

Signs of oral melanoma include bad breath, bloody saliva, difficulty eating, drooling, facial swelling, loose teeth, and reluctance to chew. Some owners notice a dark mass on the gums or palate, while others find the tumor during routine veterinary examinations. Importantly, up to one-third of oral melanomas lack dark pigmentation and appear as pink or red masses, which can lead to delayed diagnosis. Any oral mass in a dog should be evaluated promptly with biopsy.

Q: How effective is the melanoma vaccine for dogs?

The ONCEPT melanoma vaccine has shown promise as an adjunctive therapy for dogs with locally controlled oral melanoma. Clinical data suggest improved survival times when the vaccine is combined with effective surgery or radiation, particularly for Stage II and III disease. The vaccine works by stimulating an immune response against tyrosinase, a protein expressed by melanoma cells. While individual responses vary, the vaccine is generally well tolerated with minimal side effects and represents an important addition to the multimodal treatment approach for canine melanoma.

Q: Can dogs survive oral melanoma?

Survival depends on the stage at diagnosis and the treatment approach. With multimodal treatment, dogs with Stage I oral melanoma may survive 17 to 18 months or longer, while Stage II and III carry shorter median survival times. Some dogs with early-stage disease and aggressive treatment achieve long-term survival measured in years. Quality of life during and after treatment is generally good, with dogs adapting well to surgical procedures and tolerating adjuvant therapies. Early detection through regular oral examinations gives the best chance for extended survival.

Q: Should I worry about a dark spot on my dog's gums?

Any new pigmented area or mass in your dog's mouth warrants veterinary evaluation. While some dogs naturally have pigmented gums and oral mucosa, any raised, irregular, or changing area of pigmentation should be examined by a veterinarian. Flat, uniform pigmentation that has been present since puppyhood is usually normal. New, raised, or irregular pigmented lesions, especially in middle-aged to older dogs, require biopsy to rule out oral melanoma. Early detection and treatment of oral melanoma significantly improves outcomes.

Sources

Vail, D.M., Thamm, D.H., & Liptak, J.M. (2019). Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition. Elsevier.

Bergman, P.J. et al. (2003). Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase. Clinical Cancer Research, 9(4), 1284-1290.

Spangler, W.L. & Kass, P.H. (2006). The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Veterinary Pathology, 43(2), 136-149.

Brockley, L.K., Cooper, M.A., & Bennett, P.F. (2013). Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival. New Zealand Veterinary Journal, 61(1), 25-31.

Turek, M. et al. (2020). Canine oral melanoma: A review of current therapy. Topics in Companion Animal Medicine, 41, 100467.

Related Reading

• Mast Cell Tumors in Dogs, Another major skin cancer every dog owner should know about
• Skin Tags and Warts on Dogs, Distinguishing benign skin growths from those that need evaluation
• Monthly Skin Check Guide, How to systematically examine your dog's skin and oral cavity at home
• Understanding Skin Biopsy Results, What pathology reports mean and how to interpret your dog's diagnosis

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.